WO2019078543A3 - 돌미나리 추출물 및 항혈전제를 포함하는 항혈전용 조성물 - Google Patents

돌미나리 추출물 및 항혈전제를 포함하는 항혈전용 조성물 Download PDF

Info

Publication number
WO2019078543A3
WO2019078543A3 PCT/KR2018/011971 KR2018011971W WO2019078543A3 WO 2019078543 A3 WO2019078543 A3 WO 2019078543A3 KR 2018011971 W KR2018011971 W KR 2018011971W WO 2019078543 A3 WO2019078543 A3 WO 2019078543A3
Authority
WO
WIPO (PCT)
Prior art keywords
antithrombotic
composition
pharmaceutically acceptable
acceptable salt
parsley extract
Prior art date
Application number
PCT/KR2018/011971
Other languages
English (en)
French (fr)
Other versions
WO2019078543A2 (ko
Inventor
박지훈
최정호
김리연
유주희
Original Assignee
고려제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려제약주식회사 filed Critical 고려제약주식회사
Priority to JP2020542515A priority Critical patent/JP2020537696A/ja
Priority to EP18868101.9A priority patent/EP3698804A4/en
Publication of WO2019078543A2 publication Critical patent/WO2019078543A2/ko
Publication of WO2019078543A3 publication Critical patent/WO2019078543A3/ko
Priority to JP2022016141A priority patent/JP7339698B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은, 돌미나리 추출물 및 항혈전제인 클로피도그렐 또는 이의 약학적으로 허용가능한 염 및 실로스타졸 또는 이의 약학적으로 허용가능한 염으로 이루어진 군으로부터 선택되는 1종 이상을 포함하는 조성물, 이를 이용하는 혈전 억제 또는 혈전 관련 질환 예방 또는 치료 방법 및 이의 제조방법에 관한 것으로, 더욱 상세하게는 돌미나리 추출물 및 클로피도그렐 또는 이의 약학적으로 허용가능한 염 및 실로스타졸 또는 이의 약학적으로 허용가능한 염으로 이루어진 군으로부터 선택되는 1종 이상을 유효성분으로 포함하며, 단독투여시 및 다른 항혈전제의 조합에 비해서도 탁월한 혈전 생성 억제 작용을 나타내는 항혈전용, 또는 혈전 관련 질환 예방 또는 치료용 약학적 조성물에 관한 것이다.
PCT/KR2018/011971 2017-10-18 2018-10-11 돌미나리 추출물 및 항혈전제를 포함하는 항혈전용 조성물 WO2019078543A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020542515A JP2020537696A (ja) 2017-10-18 2018-10-11 野せり抽出物および抗血栓剤を含む抗血栓用組成物
EP18868101.9A EP3698804A4 (en) 2017-10-18 2018-10-11 ANTITHROMBOTIC COMPOSITION CONTAINING AN EXTRACT OF WILD PARSLEY AND AN ANTITHROMBOTIC AGENT
JP2022016141A JP7339698B2 (ja) 2017-10-18 2022-02-04 野せり抽出物および抗血栓剤を含む抗血栓用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0135472 2017-10-18
KR1020170135472A KR102532121B1 (ko) 2017-10-18 2017-10-18 돌미나리 추출물 및 항혈전제를 포함하는 항혈전용 조성물

Publications (2)

Publication Number Publication Date
WO2019078543A2 WO2019078543A2 (ko) 2019-04-25
WO2019078543A3 true WO2019078543A3 (ko) 2019-06-27

Family

ID=66174069

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/011971 WO2019078543A2 (ko) 2017-10-18 2018-10-11 돌미나리 추출물 및 항혈전제를 포함하는 항혈전용 조성물

Country Status (4)

Country Link
EP (1) EP3698804A4 (ko)
JP (2) JP2020537696A (ko)
KR (1) KR102532121B1 (ko)
WO (1) WO2019078543A2 (ko)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120103560A (ko) * 2009-10-15 2012-09-19 구이조우 리안쉥 파머슈티컬 컴퍼니 리미티드 혈전형성을 억제하는 약물
KR20130010098A (ko) * 2011-07-12 2013-01-25 삼진제약주식회사 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법
KR20130065236A (ko) * 2011-12-09 2013-06-19 안동대학교 산학협력단 미나리 추출물을 함유하는 혈전증 예방 및 치료용 조성물
KR20140033905A (ko) * 2012-09-11 2014-03-19 강원대학교산학협력단 돌미나리 추출물을 포함하는 허혈성 뇌혈관 질환 예방 또는 개선용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505126A (ja) * 2004-07-07 2008-02-21 メディキュア インターナショナル インコーポレイテッド 血小板凝集薬を用いる併用療法
CA2675836C (en) * 2007-01-17 2016-10-11 Mochida Pharmaceutical Co., Ltd. Composition for preventing or treating thrombus- or embolus-associated disease
EP2613783B1 (en) * 2010-08-26 2019-06-12 IPCA Laboratories Limited Methods for the treatment or prophylaxis of thrombosis or embolism

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120103560A (ko) * 2009-10-15 2012-09-19 구이조우 리안쉥 파머슈티컬 컴퍼니 리미티드 혈전형성을 억제하는 약물
KR20130010098A (ko) * 2011-07-12 2013-01-25 삼진제약주식회사 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법
KR20130065236A (ko) * 2011-12-09 2013-06-19 안동대학교 산학협력단 미나리 추출물을 함유하는 혈전증 예방 및 치료용 조성물
KR20140033905A (ko) * 2012-09-11 2014-03-19 강원대학교산학협력단 돌미나리 추출물을 포함하는 허혈성 뇌혈관 질환 예방 또는 개선용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUNG-HUN CHOI: "Studies on Antiplatelet Effects and Available Constituents of Hot Water Extracts from Oenanthe javanica", MASTER'S THESIS FOR THE DEGREE IN SCIENCES, January 2004 (2004-01-01), pages 1 - 79, XP009519891, Retrieved from the Internet <URL:http://m.riss.kr/search/detail/DetailView.do?p_mat_type=be54d9b8bc7cdb09&control_no=84af5034ebd53f0a> *

Also Published As

Publication number Publication date
KR20190043421A (ko) 2019-04-26
JP2022062186A (ja) 2022-04-19
KR102532121B1 (ko) 2023-05-12
JP7339698B2 (ja) 2023-09-06
EP3698804A4 (en) 2021-05-26
EP3698804A2 (en) 2020-08-26
JP2020537696A (ja) 2020-12-24
WO2019078543A2 (ko) 2019-04-25

Similar Documents

Publication Publication Date Title
MX2020001403A (es) Nuevos derivados de quinolina.
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
PH12019501034A1 (en) New anthelmintic quinoline-3-carboxamide derivatives
PH12019502851A1 (en) New azaquinoline derivatives
MX2021004707A (es) Nuevos compuestos antihelminticos.
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
WO2016137235A3 (ko) 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물
MX2020011873A (es) Nuevos derivados de quinolina.
EP3915566A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE, CONTAINING TAURODEOXYCHOLIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS THE ACTIVE INGREDIENT
WO2018033792A3 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
WO2016126085A3 (ko) 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물
NZ745210A (en) Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
WO2016142708A3 (en) Pharmaceutical composition
EP3620457A4 (en) COMPOUND DERIVED FROM PYRIMIDINE, OPTICAL ISOMER, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING A TYRO 3-RELATED DISEASE, CONSIDERING IT AS AN ACTIVE INGREDIENT
WO2015150449A3 (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
EP3845516A4 (en) NEW HIF-1alfa INHIBITOR, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING THE SAME AS AN ACTIVE INGREDIENT
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2020250182A3 (ko) 지페노사이드 화합물을 유효성분으로 포함하는 퇴행성 신경질환 치료용 조성물
WO2016163818A3 (ko) 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물
WO2019078543A3 (ko) 돌미나리 추출물 및 항혈전제를 포함하는 항혈전용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18868101

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020542515

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018868101

Country of ref document: EP

Effective date: 20200518